Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
human fecal microbiota (Reybota) (1 trial)
mesalamine (rowasa) (1 trial)
Colitis (Phase 2)
Colitis, Ulcerative (Phase 2)
Crohn Disease (Phase 2)
Inflammatory Bowel Diseases (Phase 2)
Intestinal Diseases (Phase 2)
Ulcer (Phase 2)
Trials (1 total)
Trial APIs (2 total)